Drug Profile
Research programme: pain therapeutics - Akron Molecules
Alternative Names: AKR-210Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Akron Molecules
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in Austria
- 16 Oct 2013 Preclinical trials in Pain in Austria (unspecified route) before October 2013